Marina Settles Trademark Dispute with Mirina, Will Retain its Name | GenomeWeb

By Doug Macron

Marina Biotech and Mirina have settled their trademark dispute over the similarity of their names, with each company agreeing to drop all claims and counterclaims and bear their own attorney fees and court costs.

Specific terms of the settlement were not made public, but Marina President and CEO Michael French confirmed to Gene Silencing News that his company would continue to use its name and that “no compensation was exchanged between the parties.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.